For instance, the administration of NRG4 may yield beneficial cardiometabolic effects but simultaneously increase the risk of breast cancer development through prolonged activation of the receptors ErbB3 and ErbB4 [206]. This evidence concerns the gene ERBB4 and breast cancer.